甘李药业：股东旭特宏达减持约340万股，减持计划实施完毕

Group 1 - The core business of Ganli Pharmaceutical is entirely in the pharmaceutical manufacturing industry, accounting for 100.0% of its revenue for the year 2024 [1] Group 2 - Ganli Pharmaceutical announced a share reduction plan on August 15, 2025, where Xutong Hongda intends to reduce its holdings by up to 3,399,518 shares, representing 0.57% of the total share capital [2] - The share reduction by Xutong Hongda was completed between July 29, 2025, and August 14, 2025, with a total of 3,399,501 shares sold [2] - Another shareholder, Jiao Jiao, plans to reduce her holdings by up to 67,500 shares, which is 25% of her total shares and 0.0112% of the company's total share capital, with the reduction completed between August 11, 2025, and August 14, 2025 [2]